AREV Life Sciences appoints Allan Echino as Director and Denby Greenslade as interim CFO

VANCOUVER, BC - TheNewswire - December 23, 2021 - AREV LIFE SCIENCES GLOBAL CORP. AREV AREV AREVF ("AREV" or the "Company") is pleased to announce the appointment of Allan Echino as Director effective December 21, 2021 and Denby Greenslade as interim Chief Financial Officer ("CFO"), effective December 17, 2021.

Allan Echino began his entrepreneurial experience as a youngster, working in the family business in Kamloops, BC.  As well as other business ventures, Allan became a residential realtor, and eventually progressed to be involved in the Alberta oil sector.  Allan was a founder and a Director of Corlac Resources, an oil producer, and Calroc Industries, an oil service company based in Alberta.  

Allan arranged funding for a licensed producer in the cannabis sector and quickly learned the business and the health benefits of cannabis, and mushrooms.  Allan brings a wealth of knowledge to this sector.

The Company announces the resignation of Mr. Brian Cameron as Chief Financial Officer of the Company. The Company would like to thank Mr. Cameron for his efforts and wishes him well in future endeavours.

Further, the Company is pleased to announce that the Company has issued 175,000 stock options to Directors, Officers and Consultants of the Company at a price of $0.31 for a period of 5 years from the issuance dated. These options will vest immediately.

For further information, contact Mike Withrow, arevlifesciences@gmail.com 778-929-6536. For more information visit www.arevlifesciences.com.

On behalf of the Board,

Mike Withrow
CEO & Director

About AREV Life Sciences Global Corp.

AREV is an early-stage life science discovery enterprise dedicated to delivering solutions to public health through discovery, collaborations in the life science industry, and pathogen remediation. AREV is invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for related neglected chronic co-morbidities and innovations human nutrition including the late-stage development of a Ready-to-Use Therapeutic Food (RUTF) for Severe Acute Malnutrition (SAM) and an Enteral Formula targeting the long-term effects of chronic infection. AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECanada and The Biotechnology Innovation Organization (BIO).

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required

under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements.  Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements

address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com.   

Copyright (c) 2021 TheNewswire - All rights reserved.